Xenon Q3 net loss $48.5M; XEN1101 MDD trial topline due late Nov–mid Dec

Xenon Pharmaceuticals Inc.

2023-Q3 EPS reported -$2.09

Net loss $48.5M in Q3 2023 vs $37.2M in Q3 2022; cash $639.1M, funding operations into 2026.
XEN1101 Phase 2 X-NOVA MDD trial topline results expected late November to mid-December 2023.
Phase 3 epilepsy trials X-TOLE2, X-TOLE3, X-ACKT ongoing; X-TOLE2 enrollment to complete H2 2024.
Neurocrine to report NBI-921352 adult focal study data in November 2023.
R&D expenses increased to $42.9M from $29.4M, driven by XEN1101 clinical advancement.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xenon Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue No revenue was recognized.

Period: the third quarter ended September 30, 2023
Revenue: No revenue was recognized
Result: reported results

Exact text from the filing

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.